Mundipharma EDO Begins Phase 1/2 Trial of Tinostamustine in Triple Negative Breast Cancer, Other Solid Tumors
News
Mundipharma EDO GmbH has initiated a Phase 1/2 clinical trial of tinostamustine (EDO-S101) in patients with advanced triple negative breast cancer (TNBC), ovarian cancer (OC), and other solid tumors. The study ... Read more